Similarly, in a phase II clinical trial, pyrotinib, an irreversible small molecule inhibitor of EGFR/HER2/HER4 receptors, showed an ORR of 30% and an mPFS of 6.9 months in 60 patients with platinum-treated advanced NSCLC with HER2 mutations. Here, ERBB2 is linked to non-small cell lung carcinoma.